Tellus BioVentures

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Cantai Therapeutics operates as a developer of drug candidates.

ViTToria Biotherapeutics is a company focused on developing gene-edited cell therapies, specifically next-generation T-cell therapeutics that aim to address significant unmet medical needs. Utilizing its proprietary Senza5 Technology, ViTToria enhances the efficacy, safety, and overall utility of cell-based treatments in preclinical settings. The company's innovative approach seeks to lower dosing requirements, simplify preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. This technology enables medical practitioners to improve patient outcomes, positioning ViTToria Biotherapeutics as a pioneer in the advancement of cell therapy solutions.

Praeventix is an early-stage biotechnology company dedicated to developing innovative therapeutics for bowel diseases and other serotonergic-driven disorders. The company specializes in the discovery, research, and early clinical development of novel therapeutics that modulate signal transduction pathways. Praeventix aims to address unmet clinical needs in inflammatory bowel disease and has potential applications in treating dermatologic, autoimmune, and neurodegenerative diseases. Through its focused approach, the company seeks to provide physicians with effective treatment options for conditions such as chronic pruritus.

Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

ViTToria Biotherapeutics is a company focused on developing gene-edited cell therapies, specifically next-generation T-cell therapeutics that aim to address significant unmet medical needs. Utilizing its proprietary Senza5 Technology, ViTToria enhances the efficacy, safety, and overall utility of cell-based treatments in preclinical settings. The company's innovative approach seeks to lower dosing requirements, simplify preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. This technology enables medical practitioners to improve patient outcomes, positioning ViTToria Biotherapeutics as a pioneer in the advancement of cell therapy solutions.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Navrogen is a biopharmaceutical company based in Philadelphia, Pennsylvania, incorporated in 2017. The company specializes in developing technology platforms aimed at enhancing the immune system's ability to fight cancer. Navrogen focuses on identifying and addressing factors produced or induced by tumor cells that suppress the humoral immune response against cancer cells. By targeting these immunosuppressive effects, Navrogen aims to improve the efficacy of antibody-based drugs and develop more effective cancer treatments.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

TamuroBio is a biotechnology company dedicated to developing innovative therapeutics for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and Type 2 diabetes. The company focuses on creating pre-clinical candidates aimed at sequestering lipotoxic products to treat NASH, thereby helping patients prevent chronic liver disease and improve their quality of life. Through its targeted research and development efforts, TamuroBio aims to address significant unmet medical needs in the management of these conditions.

Aegle Therapeutics Corporation is a biotechnology company focused on developing innovative therapies utilizing extracellular vesicles (EVs) derived from allogeneic bone marrow-derived mesenchymal stem cells. Established in 2019 and headquartered in Arlington, Massachusetts, with an additional office in Miami, Florida, Aegle aims to address severe dermatological conditions, particularly dystrophic epidermolysis bullosa, a rare pediatric skin disorder characterized by blistering. The company's proprietary platform technology is designed to harness the regenerative properties of stem cells in a cell-free format, potentially offering a safer and more cost-effective solution for healing. Aegle's EV therapy is intended to facilitate functional regeneration and organization of complex tissue structures, thereby enhancing healing, reducing scarring, and improving overall cosmetic outcomes. The company's Investigational New Drug application for treating dystrophic epidermolysis bullosa has been cleared by the FDA, positioning Aegle to enter clinical trials.

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.